FDG-PET/CT in the evaluation of paraneoplastic neurologic syndromes

Steven J. Sherry, Abdel K. Tahari, Sahar Mirpour, Andrew Colucci, Rathan M. Subramaniam

Research output: Contribution to journalReview article


Paraneoplastic neurologic syndromes (PNS) are a rare, heterogeneous group of complications associated with malignancy, unrelated to direct tumor invasion or metastasis, that may be immune-mediated. The aim of this article is to provide an overview of PNS and outline the value of 2-deoxy-2-[ 18F]fluoro-D-glucose PET/CT in the evaluation of patients with a PNS. 2-deoxy-2-18F-fluoro-D-glucose PET/CT is valuable to identify or exclude an occult malignancy in patients with suspected paraneoplastic syndromes.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalImaging in Medicine
Issue number1
StatePublished - Feb 1 2014


  • PET/CT
  • occult malignancy
  • paraneoplastic syndromes

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'FDG-PET/CT in the evaluation of paraneoplastic neurologic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Sherry, S. J., Tahari, A. K., Mirpour, S., Colucci, A., & Subramaniam, R. M. (2014). FDG-PET/CT in the evaluation of paraneoplastic neurologic syndromes. Imaging in Medicine, 6(1), 117-126. https://doi.org/10.2217/iim.13.73